Welcome to our dedicated page for Camp4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on Camp4 Therapeutics stock.
CAMP4 Therapeutics Corporation reports developments as a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in genetic diseases. Company updates center on its RAP Platform, regRNA mapping, antisense oligonucleotide candidates and CMP-002 for SYNGAP1-related disorder, along with regulatory submissions, orphan-drug designation and natural-history research collaborations.
Recurring news also includes financial results, research and development spending, financing activity, business-development agreements such as the GSK collaboration, board and governance changes, inducement equity grants under Nasdaq rules and investor conference participation.
CAMP4 Therapeutics (Nasdaq:CAMP) reported new preclinical data for CMP-002, its lead antisense oligonucleotide for SYNGAP1-related disorder (SRD). In a SYNGAP1 haploinsufficient mouse model using pentylenetetrazol-induced seizures, CMP-002 administration produced statistically significant improvements in seizure threshold and tonic-clonic seizure severity. CAMP4 plans to advance CMP-002 into a Phase 1/2 trial in SRD in the second half of 2026.
CAMP4 (Nasdaq: CAMP) reported Q1 2026 results and corporate highlights on May 7, 2026. Key updates: submitted first regulatory filing for CMP-002 in Australia to enable a global Phase 1/2 SYNGAP1 trial in 2H 2026; EMA granted Orphan Designation for CMP-002; collaboration established with CURE SYNGAP1 for the ProMMiS natural history study. As of March 31, 2026, cash and cash equivalents were $99.2M, with the company estimating runway into 2028. Q1 operating highlights include R&D $10.2M, G&A $4.2M, and net loss $18.3M, which included a $6.2M non-cash derivative loss.
CAMP4 Therapeutics (Nasdaq: CAMP) submitted a preprint (April 28, 2026) describing regRNA Capture-seq and epigenomic mapping that assembled what the company believes is the largest catalog of regulatory RNAs in human liver cells and enabled discovery of antisense oligonucleotides (ASOs) that increased OTC expression in human hepatocytes.
The preprint outlines mechanistic studies of ASOs reshaping regRNA, displacing repressors at an enhancer, and identifies lead candidate CMP-002 for SYNGAP1, expected to enter Phase 1/2 in H2 2026.
CAMP4 (Nasdaq: CAMP) granted non-qualified stock options totaling 43,000 shares on April 15, 2026 as inducement awards to three newly hired employees under Nasdaq Rule 5635(c)(4).
The options have a 10-year term, an exercise price of $4.59 per share (closing price on the grant date) and vest over four years (25% at one year, then monthly over 36 months).
CAMP4 (Nasdaq: CAMP) appointed Michael MacLean to its Board of Directors on March 24, 2026.
Mr. MacLean brings 35+ years of financial leadership in biotech, including service as CFO at Avidity Biosciences through its 2020 IPO and its acquisition by Novartis in 2026, and senior finance roles at Akcea, PureTech, and Biogen. The appointment coincides with CAMP4 advancing CMP-002 toward a planned first-in-human Phase 1/2 trial for SYNGAP1-related disorder.
CAMP4 (Nasdaq: CAMP) will participate in three investor conferences in March and April 2026, presenting company updates and hosting a fireside chat and corporate presentations.
Events include Leerink Global Healthcare (March 9, 2026, fireside chat, Miami), Stifel CNS Forum (March 17, 2026, virtual) and Needham Healthcare (April 13, 2026, virtual). Live webcasts and 30-day replays will be available on CAMP4's investor relations site.
CAMP4 (Nasdaq: CAMP) reported full-year 2025 results and corporate highlights on March 5, 2026, emphasizing progress on its SYNGAP1 program and a strategic collaboration with GSK.
Key points: GLP toxicology for CMP-002 ongoing; global Phase 1/2 in SYNGAP1 patients targeted as early as H2 2026; $17.5M upfront from GSK plus up to $440M in milestones and tiered royalties; financing raised including $50M upfront private placement and $30M underwritten offering; cash of $109.5M expected to fund operations into 2028; 2025 net loss $80.4M.
CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement option grant on February 16, 2026 to a newly hired employee. The company granted a non-qualified stock option for 8,000 shares with a 10-year term and an exercise price of $3.85, equal to the closing price on the grant date.
The option vests over four years: 25% on the first anniversary and the remainder in 36 equal monthly installments, subject to continued service, under an Inducement Option Award Agreement.
CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement equity award granted on January 15, 2026 under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee granted a non-qualified stock option for 8,000 shares to a newly hired employee with a 10-year term and an exercise price of $5.78 per share (closing price on the grant date). The option vests over four years: 25% at the one-year anniversary, then monthly over 36 months, subject to continued service, and is governed by an Inducement Option Award Agreement.
CAMP4 (Nasdaq: CAMP) announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 3:45 p.m. PST.
The presentation will be webcast and accessible via CAMP4's investor relations website at www.investors.camp4tx.com. A replay will be archived on the CAMP4 website for 30 days following the conference.